STAAR Surgical Company

NasdaqGM:STAA Stock Report

Market Cap: US$1.5b

STAAR Surgical Valuation

Is STAA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STAA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: STAA ($31.2) is trading below our estimate of fair value ($65.49)

Significantly Below Fair Value: STAA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for STAA?

Other financial metrics that can be useful for relative valuation.

STAA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.1x
Enterprise Value/EBITDA40.6x
PEG Ratio2.4x

Price to Earnings Ratio vs Peers

How does STAA's PE Ratio compare to its peers?

The above table shows the PE ratio for STAA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average67x
VIVO Meridian Bioscience
35.2xn/aUS$1.5b
UFPT UFP Technologies
50.6x19.6%US$2.5b
AVNS Avanos Medical
148.8xn/aUS$1.0b
HAE Haemonetics
33.2x28.3%US$3.8b
STAA STAAR Surgical
92.3x38.1%US$1.5b

Price-To-Earnings vs Peers: STAA is expensive based on its Price-To-Earnings Ratio (92.3x) compared to the peer average (77.5x).


Price to Earnings Ratio vs Industry

How does STAA's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: STAA is expensive based on its Price-To-Earnings Ratio (92.3x) compared to the US Medical Equipment industry average (37x).


Price to Earnings Ratio vs Fair Ratio

What is STAA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STAA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio92.3x
Fair PE Ratio47.2x

Price-To-Earnings vs Fair Ratio: STAA is expensive based on its Price-To-Earnings Ratio (92.3x) compared to the estimated Fair Price-To-Earnings Ratio (47.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STAA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$31.20
US$50.49
+61.8%
16.0%US$60.00US$37.00n/a11
Aug ’25US$39.95
US$51.22
+28.2%
14.9%US$60.00US$37.00n/a11
Jul ’25US$47.42
US$51.68
+9.0%
13.1%US$60.00US$40.00n/a10
Jun ’25US$41.53
US$52.31
+26.0%
13.1%US$60.00US$40.00n/a9
May ’25US$44.69
US$49.17
+10.0%
19.5%US$60.00US$33.00n/a9
Apr ’25US$39.04
US$43.72
+12.0%
17.6%US$53.00US$32.00n/a9
Mar ’25US$33.31
US$40.88
+22.7%
21.3%US$53.00US$30.00n/a8
Feb ’25US$28.70
US$42.25
+47.2%
20.8%US$53.00US$30.00n/a8
Jan ’25US$31.21
US$45.11
+44.5%
19.5%US$56.00US$33.00n/a9
Dec ’24US$32.99
US$47.75
+44.7%
16.6%US$56.00US$35.00n/a8
Nov ’24US$43.32
US$51.71
+19.4%
16.6%US$64.00US$40.00n/a7
Oct ’24US$40.18
US$53.25
+32.5%
17.1%US$65.00US$40.00n/a8
Sep ’24US$43.06
US$56.56
+31.3%
12.4%US$66.00US$45.00US$33.099
Aug ’24US$52.80
US$71.78
+35.9%
11.6%US$84.00US$55.00US$39.959
Jul ’24US$52.57
US$76.00
+44.6%
12.7%US$85.00US$55.00US$47.429
Jun ’24US$57.78
US$78.78
+36.3%
13.0%US$95.00US$60.00US$41.539
May ’24US$72.82
US$77.56
+6.5%
11.9%US$90.00US$60.00US$44.699
Apr ’24US$63.95
US$79.50
+24.3%
10.8%US$90.00US$60.00US$39.048
Mar ’24US$56.69
US$79.50
+40.2%
10.8%US$90.00US$60.00US$33.318
Feb ’24US$72.96
US$80.33
+10.1%
14.9%US$105.00US$60.00US$28.709
Jan ’24US$48.54
US$80.22
+65.3%
14.9%US$105.00US$60.00US$31.219
Dec ’23US$59.13
US$85.50
+44.6%
9.7%US$105.00US$78.00US$32.998
Nov ’23US$73.75
US$100.63
+36.4%
14.3%US$125.00US$85.00US$43.328
Oct ’23US$70.55
US$106.33
+50.7%
12.1%US$125.00US$86.00US$40.186
Sep ’23US$91.79
US$105.29
+14.7%
11.5%US$125.00US$86.00US$43.067

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies